180,000 Shares in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Purchased by Readystate Asset Management LP

Readystate Asset Management LP purchased a new position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 180,000 shares of the specialty pharmaceutical company's stock, valued at approximately $2,084,000. Readystate Asset Management LP owned about 0.42% of KalVista Pharmaceuticals as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in KALV. Vestal Point Capital LP grew its position in shares of KalVista Pharmaceuticals by 73.9% in the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company's stock valued at $46,320,000 after purchasing an additional 1,700,000 shares during the period. Great Point Partners LLC purchased a new stake in shares of KalVista Pharmaceuticals in the second quarter valued at $15,768,000. Emerald Advisers LLC grew its position in shares of KalVista Pharmaceuticals by 29.8% in the third quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company's stock valued at $9,681,000 after purchasing an additional 192,091 shares during the period. Emerald Mutual Fund Advisers Trust grew its position in shares of KalVista Pharmaceuticals by 23.0% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 650,980 shares of the specialty pharmaceutical company's stock valued at $7,538,000 after purchasing an additional 121,615 shares during the period. Finally, Susquehanna Fundamental Investments LLC grew its position in shares of KalVista Pharmaceuticals by 323.5% in the second quarter. Susquehanna Fundamental Investments LLC now owns 68,526 shares of the specialty pharmaceutical company's stock valued at $807,000 after purchasing an additional 52,347 shares during the period.

KalVista Pharmaceuticals Price Performance

KALV stock traded down $0.36 during trading on Thursday, reaching $9.10. 123,590 shares of the stock traded hands, compared to its average volume of 478,438. The business's 50 day moving average price is $10.97 and its 200-day moving average price is $11.85. The firm has a market capitalization of $393.30 million, a PE ratio of -2.60 and a beta of 0.85. KalVista Pharmaceuticals, Inc. has a 52-week low of $7.39 and a 52-week high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last issued its quarterly earnings data on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) EPS for the quarter, topping analysts' consensus estimates of ($0.91) by $0.04. On average, equities research analysts predict that KalVista Pharmaceuticals, Inc. will post -2.7 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Paul K. Audhya sold 8,077 shares of the business's stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $74,793.02. Following the transaction, the insider now owns 94,199 shares in the company, valued at approximately $872,282.74. The trade was a 7.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Benjamin L. Palleiko sold 14,400 shares of the business's stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $133,344.00. Following the completion of the transaction, the chief executive officer now owns 266,598 shares in the company, valued at approximately $2,468,697.48. This trade represents a 5.12 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 32,016 shares of company stock worth $319,344 over the last quarter. 10.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on KALV shares. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of KalVista Pharmaceuticals in a research report on Monday, September 9th. HC Wainwright reissued a "buy" rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Monday, October 7th. Finally, Needham & Company LLC reissued a "buy" rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research report on Thursday.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).